Your browser doesn't support javascript.
loading
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy, Kieron; Fanale, Michelle A; Abramson, Jeremy S; Noy, Ariela; Caimi, Paolo Fabrizio; Pittaluga, Stefania; Parekh, Samir; Lacasce, Ann; Hayslip, John W; Jagadeesh, Deepa; Nagpal, Sunil; Lechowicz, Mary Jo; Gaur, Rakesh; Lucas, Andrea; Melani, Christopher; Roschewski, Mark; Steinberg, Seth M; Jaffe, Elaine S; Kahl, Brad; Friedberg, Jonathan W; Little, Richard F; Bartlett, Nancy L; Wilson, Wyndham H.
Afiliación
  • Dunleavy K; Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
  • Fanale MA; MD Anderson Cancer Center, Houston, TX, USA.
  • Abramson JS; Massachusetts General Hospital and Dana Farber Cancer Institute, Boston, MA, USA.
  • Noy A; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Caimi PF; Case Western Reserve University, Cleveland, Ohio, USA.
  • Pittaluga S; Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.
  • Parekh S; Hess Center for Science and Medicine, New York, NY, USA.
  • Lacasce A; Massachusetts General Hospital and Dana Farber Cancer Institute, Boston, MA, USA.
  • Hayslip JW; University of Kentucky, Lexington, KY, USA.
  • Jagadeesh D; Cleveland Clinic, Cleveland, Ohio, USA.
  • Nagpal S; West Michigan Cancer Center, Kalamazoo, MI, USA.
  • Lechowicz MJ; Emory University, Atlanta, GA, USA.
  • Gaur R; Saint Luke's, Kansas City, KS, USA.
  • Lucas A; Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
  • Melani C; Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
  • Roschewski M; Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA.
  • Steinberg SM; Center for Cancer Research, and Biostatistics and Data Management Section, National Cancer Institute, Bethesda, MD, USA.
  • Jaffe ES; Hematopathology Section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.
  • Kahl B; Washington University, St Louis, MO, USA.
  • Friedberg JW; University of Rochester, Rochester, NY, USA.
  • Little RF; Cancer and Therapeutic Evaluation Program, National Cancer Institute, Bethesda, MD, USA.
  • Bartlett NL; Washington University, St Louis, MO, USA.
  • Wilson WH; Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, MD, USA. Electronic address: wilsonw@mail.nih.gov.
Lancet Haematol ; 5(12): e609-e617, 2018 Dec.
Article en En | MEDLINE | ID: mdl-30501868
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Reordenamiento Génico / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas c-myc / Linfoma de Células B Grandes Difuso / Rituximab Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Reordenamiento Génico / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogénicas c-myc / Linfoma de Células B Grandes Difuso / Rituximab Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Haematol Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos